{"id":"shr6508-plus-oral-placebo-tablets","safety":{"commonSideEffects":[]},"_chembl":{"chemblId":"CHEMBL2108778","moleculeType":"Vaccine component"},"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"SHR6508 works by binding to the molecular target, which results in the desired therapeutic effect.","oneSentence":"SHR6508 is a small molecule drug that targets the molecular target.","_ai_confidence":"low"},"_scrapedAt":"2026-03-28T00:53:01.374Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"unknown"}]},"trialDetails":[{"nctId":"NCT06434961","phase":"PHASE3","title":"The Trial of SHR6508 in Secondary Hyperparathyroidism","status":"COMPLETED","sponsor":"Shanghai Hengrui Pharmaceutical Co., Ltd.","startDate":"2024-06-14","conditions":"Secondary Hyperparathyroidism","enrollment":498}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"SHR6508 plus oral placebo tablets","genericName":"SHR6508 plus oral placebo tablets","companyName":"Shanghai Hengrui Pharmaceutical Co., Ltd.","companyId":"shanghai-hengrui-pharmaceutical-co-ltd","modality":"Small molecule","firstApprovalDate":"","aiSummary":"SHR6508 is a small molecule drug that targets the molecular target. Used for unknown.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":false,"trials":true,"score":3}}